The extensive use of antibiotics has led to a threatening situation where bacteria have developed resistance resulting in spread of life-threatening diseases. In FORMAMP, nanotechnology-based delivery systems together with antimicrobial peptides have been used to develop innovative drug formulations for local treatment of skin and lung infections
The long-term objective of the FORMAMP project is to significantly change the treatment strategies for infectious diseases and to reduce the evolution of multi-resistant bacteria.
The specific aims of the project were to develop new and innovative formulation strategies for local administration, based on the combination of nanotechnology-based delivery systems and antimicrobial peptides, for the treatment of infectious diseases caused by bacteria such as Pseudomonas aeruginosa, MRSA (Methicillin-resistant Staphylococcus aureus), and MTB (Mycobacterium tuberculosis). Clinical indications that have been addressed include skin and soft tissue infections, infections in burn wounds, and infections in the lung such as cystic fibrosis and tuberculosis. A number of these indications are associated with the formation of multispecies biofilms, drastically impairing the function of available treatments. An important objective of the FORMAMP project was therefore to develop treatment strategies that also takes into account the problems associated with biofilms for clinical indications where this is of importance.
Reduce the drastic increase of resistant bacteria
Coordinator and research partner
RISE, Lunds Universitet, Uppsala Universitet, Universitaet Ulm , Academisch Ziekenhuis Groninen , ProMore Pharma, Medical Products Agency, Polymer Factory Sweden, Universite d´Angers , Centre Hospitalier d’Angers , Kungliga Tekniska Högskolan, Inhalation Sciences Sweden , XSpray Microparticles , Adenium Biotech , Polypeptide Laboratories